Medifast, Inc. (MED) is likely to register a decrease in both top and bottom lines when it reports first-quarter 2025 earnings on April 28, after market close. The Zacks Consensus Estimate for first-quarter revenues is pegged at $119.9 million, which indicates a 31.4% decline from the year-ago quarter’s reported figure.Although the consensus mark for first-quarter bottom line has narrowed by 13 cents in the past 30 days to a loss of 7 cents, the projection indicates deterioration from 66 cents reported in t ...

Medifast, Inc. (MED) has seen its shares dive 28.2% in the past six months compared with the industry’s decline of 9.4%. The company has also underperformed the broader Zacks Consumer Staples sector’s dip of 2% and the S&P 500’s decline of 7%. Closing the trading session at $12.92 yesterday, the stock hovers close to its 52-week low of $12.30 reached on April 7.MED Stock's Price PerformanceImage Source: Zacks Investment ResearchThis significant decline in Medifast stock price can be attributed to several fa ...

Medifast, Inc. (NYSE: MED ) operates the Optavia wellness brand. The company offers weight loss and management plans, such as supplements, meals, and other products through weight loss coaches. At the end of 2024 , Medifast has 27.1 thousand active earningI am an avid investor with a major focus on small cap companies with experience in investing in US, Canadian, and European markets. My investment philosophy to generating great returns on the stock market revolves around identifying mispriced securities by ...

Medifast, Inc. (MED) delivered fourth-quarter 2024 results, with the bottom and top lines declining year over year. However, both earnings and net revenues beat the Zacks Consensus Estimate.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.This year was a transformative period for Medifast as the company adapted to the evolving health and wellness market, driven by the growing acceptance of GLP-1 medications. Throughout the year, the team demonstrated resilience and adaptability, ensuri ...

Medifast, Inc. (NYSE:MED) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Steven Zenker - Vice President, Investor Relations Dan Chard - Chairman and Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants James Salera - Stephens Linda Bolton-Weiser - D.A. Davidson Operator Greetings and welcome to the Medifast Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer ses ...

Medifast (MED) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of a loss of $0.27 per share. This compares to earnings of $1.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 137.04%. A quarter ago, it was expected that this weight-loss company would post a loss of $0.15 per share when it actually produced earnings of $0.35, delivering a surprise of 333.33%.Over the last four quarters ...

Market Overview - The GLP-1 support market is projected to be worth $50 billion or more by 2030, with over 95% of OPTAVIA coach leaders trained in GLP-1 based support [25]. - The addressable market for weight loss is estimated to exceed $30 billion, with approximately 200 million people in the U.S. looking to lose weight [42]. - The weight loss industry is highly competitive, with medical weight loss solutions like GLP-1 medications becoming increasingly significant [37]. - Nearly 75% of U.S. adults are classified as overweight or obese, with over 40% classified as obese between August 2021 and August 2023 [50]. - Recent research indicates that about one-third of GLP-1 medication users discontinue use after six months, with two-thirds of weight lost typically regained within 12 months [25]. Company Impact and Community - Medifast's lifestyle brand, OPTAVIA, has impacted over 3 million lives and operates with approximately 27,100 active earning coaches [20]. - The company has impacted over 3 million lives through its scientifically designed products and programs, which are developed by physicians and dietitians [57]. - The OPTAVIA community offers a holistic wellness program, with about 90% of coaches being former customers, enhancing relatability and support [52]. - OPTAVIA's coaching model has shown that customers who engage in at least 75% of their coaching calls lost an average of 15.2 lbs, compared to 6.7 lbs for those who participated less [60]. Product and Service Offerings - Medifast introduced the OPTAVIA ASCEND product line, featuring high-protein, fiber-rich mini meals and a daily nutrient pack, to support weight management for GLP-1 users [26]. - OPTAVIA offers a range of nutrition plans tailored to individual goals, supported by a mobile app with healthy recipes and habit trackers [63]. - The company's integrated approach combines lifestyle coaching, community support, and access to medical solutions, positioning it to meet diverse customer needs [31]. - Medifast's innovative model emphasizes holistic wellness and personalized support, promoting lifelong habit development through the Habits of Health Transformational System [44]. Marketing and Customer Engagement - The company incurred approximately $22.9 million in marketing expenses for the year ended December 31, 2024, as part of its efforts to increase brand awareness and customer adoption [71]. - The company has introduced new marketing campaigns in 2024 to reach new audiences and deepen engagement with existing customers [71]. - The effectiveness of the company's advertising and marketing programs, particularly through social media, is critical for attracting and retaining customers [131]. Operational Challenges and Compliance - The company is subject to extensive federal, state, and local regulations governing its operations, including those related to food and beverage sales [73]. - Regulatory compliance issues, including those from the FDA and FTC, could result in legal actions that may harm the company's financial condition [130]. - The company faces potential legal and regulatory challenges regarding its direct selling model, which could adversely impact its business operations [136]. - The company must monitor compliance with evolving advertising regulations, particularly in relation to social media marketing, to avoid fines and penalties [135]. Financial Performance and Strategy - The company announced the discontinuation of its quarterly cash dividend as of December 13, 2023, following a thorough review of its capital allocation priorities [176]. - The company’s future revenue and operating results are at risk due to a decline in the number of active earning OPTAVIA coaches since Q3 2022 [119]. - Revenue is primarily derived from point of sale transactions on an e-commerce platform for weight loss and healthy living products [214]. - Revenue recognition changed in Q1 2023; now recognized upon delivery to the shipping carrier [214]. Employee Engagement and Corporate Culture - The company achieved a 93% activation rate in its AcedIt recognition program, with 65% of team members actively using the tool monthly [103]. - In 2024, over 85% of employees engaged with the LiveWell wellness program, which incentivizes health and wellness activities [103]. - The company conducted two cycles of its listening initiative, The Loop, in 2024 to promote communication transparency and improve employee engagement [104]. Technology and Cybersecurity - The company has established processes for assessing and managing cybersecurity risks, integrating them into the overall risk management system [183]. - The Board of Directors receives quarterly updates on cybersecurity risks and strategies from senior executives [191]. - The cybersecurity incident response team (CIRT) oversees the incident response strategy and remediation efforts [194]. Supply Chain and Manufacturing - Jason Pharmaceuticals, Inc. manufactures approximately 40% of the company's total unit sales at its FDA-regulated facility in Owings Mills, Maryland [72]. - The company relies on third-party manufacturers for the majority of its products, with approximately 40% of total unit sales produced in-house at its Maryland facility [144]. - Disruptions in the supply chain, including ingredient shortages or transportation issues, could materially affect the company's business and financial results [146]. Legal and Regulatory Risks - The company may face scrutiny regarding the qualifications of its OPTAVIA coaches, which could lead to claims and lawsuits [151]. - The company may be subject to health-related claims from customers, which could lead to lawsuits and damage its reputation [152]. - The company’s brand and intellectual property rights are at risk of infringement, which could diminish brand value and competitive position if not adequately protected [162].

Medifast® Q4 2024 Earnings Supplement © 2025 Medifast, Inc. All Rights Reserved. 2 Safe Harbor Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend," "anticipate," "expect" or other similar ...

Medifast Announces Fourth Quarter and Full Year 2024 Financial Results February 18, 2025 BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Full Year 2024 "This past year was a pivotal year for Medifast, as we continued to transform our business to meet the changing nature of a health and wellness mark ...

Medifast, Inc. (MED) has introduced a high-protein product line, OPTAVIA ASCEND, designed to support individuals using GLP-1 medications and those seeking help to maintain weight loss. The new line features fiber-rich mini meals and daily nutrient packs, which aim to boost muscle health, digestive function and bone strength.OPTAVIA ASCEND is integrated into two new science-backed nutrition plans, complementing OPTAVIA's comprehensive approach to fill a critical gap in the weight management sector. This laun ...